ClinicalTrials.Veeva

Menu

The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration (it does not)

A

Assiut University

Status

Not yet enrolling

Conditions

Neovascular (wet) Age-Related Macular Degeneration

Study type

Observational

Funder types

Other

Identifiers

NCT06759597
Macular Changes after PHE

Details and patient eligibility

About

The macula has a very high concentration of photoreceptor cells - the cells that detect light. They send signals to the brain, which interprets them as images. The rest of the retina processes our peripheral, or side vision To explore whether cataract surgery evokes development or relapse of choroidal neovascularization (CNV) in wet age-related macular degeneration (AMD) patients followed for a 1-year postoperative period

Full description

Age-related macular degeneration (AMD) is a leading cause of vision loss in adults over the age of 50. AMD causes damage to a small part of the retina responsible for central vision called the macula. When damage to the macula occurs, it typically causes loss of central, detailed vision which results in difficulty with tasks such as reading, driving, threading a needle, or recognizing faces.

Phacoemulsification is a modern-day cataract surgery that employs ultrasound energy to emulsify the nucleus, vacuum to catch the nuclear material, and irrigation and aspiration for cortex and viscoelastic removal.

It is currently impossible to draw definitive conclusions whether phacoemulsification (PhE) is safe for people with age-related macular degeneration (ARMD). It is not clear if PhE causes the progression of ARMD and affects visual acuity (VA). The purpose was to analyze the possible association of PhE with ARMD progression in the early and late (up to 18 months after surgery) period.

Enrollment

50 estimated patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Subjects included in this study aged above 50 and presented for routine check up after undergoing phacoemulsification:

  • Above 50 years old

    • not diabetic individuals
    • wet ARMD

Exclusion Criteria:

  • intraoperative complications

    • Eyes with diseases predisposing them for postoperative macular edema, preexisting macular edema, and eyes that developed cystoid macular edema
    • active ocular inflammation or infection _glaucoma
    • A preoperatively worsened VA regardless phE
    • ocular trauma
    • patients with central retinal ischemia
    • previous vitrectomy
    • dry amd

Trial contacts and locations

0

Loading...

Central trial contact

Demiana Alkes Zakka Labib Demiana Alkes Zakka Labib

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems